NO20062509L - Tetrazolderivater og fremgangsmater for behandling av stoffskifterelaterte forstyrrelser derav - Google Patents

Tetrazolderivater og fremgangsmater for behandling av stoffskifterelaterte forstyrrelser derav

Info

Publication number
NO20062509L
NO20062509L NO20062509A NO20062509A NO20062509L NO 20062509 L NO20062509 L NO 20062509L NO 20062509 A NO20062509 A NO 20062509A NO 20062509 A NO20062509 A NO 20062509A NO 20062509 L NO20062509 L NO 20062509L
Authority
NO
Norway
Prior art keywords
inhibitors
present
treatment
methods
compound
Prior art date
Application number
NO20062509A
Other languages
English (en)
Inventor
Graeme Semple
Thomas Schrader
Phillip J Skinner
Steven L Colletti
Tawfik Gharbaoui
Jason Imbriglio
Jae-Kyu Jung
Rui Liang
Subharekha Raghavan
Darby Schmidt
James R Tata
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO20062509L publication Critical patent/NO20062509L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Foreliggende oppfinnelse angår visse tetrazolderivater med formel (I), og fannasøytisk akseptable salter derav, som fremviser anvendelige farmakologiske egenskaper, for eksempel som agonister for RUP25-reseptoren. I tillegg tilveiebringer foreliggende oppfinnelse farmasøytiske sammensetninger som inneholder forbindelser ifølge oppfinnelsen og fremgangsmåter for anvendelse av forbindelsen og sammensetningen ifølge oppfinnelsen ved behandling av metabolitisk relaterte forstyrrelser, som inkluderer dyslipidemi, aterosklerose, koronar hjertesykdom, insulinresistens, type 2-diabetes, syndrom X og lignende. I tillegg tilveiebringer foreliggende oppfinnelse også anvendelse av forbindelse ifølge oppfinnelsen i kombinasjon med andre aktive midler slik som de som tilhører klassen av a-glukosidaseinhibitorer, aldosereduktaseinhibitorer, biguanider, HMG-CoA-reduktaseinhibitorer, skvalensynteseinhibitorer, fibrater, LDL-katabolismeforsterkere, angiotensinomdannende enzym (ACE) inhibitorer, insulinsekresjonsforsterkere og lignende.
NO20062509A 2003-10-31 2006-05-31 Tetrazolderivater og fremgangsmater for behandling av stoffskifterelaterte forstyrrelser derav NO20062509L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51623803P 2003-10-31 2003-10-31
PCT/US2004/035927 WO2005044816A1 (en) 2003-10-31 2004-10-29 Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof

Publications (1)

Publication Number Publication Date
NO20062509L true NO20062509L (no) 2006-06-26

Family

ID=34572875

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062509A NO20062509L (no) 2003-10-31 2006-05-31 Tetrazolderivater og fremgangsmater for behandling av stoffskifterelaterte forstyrrelser derav

Country Status (38)

Country Link
US (2) US8637555B2 (no)
EP (2) EP1599469B1 (no)
JP (2) JP4533898B2 (no)
KR (1) KR100850591B1 (no)
CN (1) CN1867562B (no)
AR (1) AR046611A1 (no)
AT (1) ATE328880T1 (no)
AU (1) AU2004287861B2 (no)
BR (1) BRPI0415631A (no)
CA (1) CA2539985C (no)
CO (1) CO5690551A2 (no)
CR (1) CR8270A (no)
CY (1) CY1105479T1 (no)
DE (1) DE602004001134T2 (no)
DK (1) DK1599469T3 (no)
EA (1) EA011484B1 (no)
EC (1) ECSP066529A (no)
ES (1) ES2267077T3 (no)
GE (1) GEP20094801B (no)
HK (1) HK1076468A1 (no)
HR (1) HRP20060286T3 (no)
IL (1) IL174042A0 (no)
IS (1) IS2372B (no)
MA (1) MA28171A1 (no)
MX (1) MXPA06004556A (no)
MY (1) MY140410A (no)
NO (1) NO20062509L (no)
NZ (1) NZ546285A (no)
PE (1) PE20050483A1 (no)
PL (1) PL1599469T3 (no)
PT (1) PT1599469E (no)
RS (1) RS20060290A (no)
SI (1) SI1599469T1 (no)
TN (1) TNSN06150A1 (no)
TW (1) TWI258478B (no)
UA (1) UA86783C2 (no)
WO (1) WO2005044816A1 (no)
ZA (2) ZA200603419B (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI258478B (en) 2003-10-31 2006-07-21 Arena Pharm Inc Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
ES2331521T3 (es) 2003-11-21 2010-01-07 Arena Pharmaceuticals, Inc. Derivados de acido 4-oxo-4,5-dihidro-furan-2-carboxilico y procedimientos de tratamiento de trastornos metabolicos relacionados del mismo.
WO2006026273A2 (en) * 2004-08-25 2006-03-09 Merck & Co., Inc. Method of treating atherosclerosis, dyslipidemias and related conditions
AU2005305086A1 (en) * 2004-11-05 2006-05-18 Arena Pharmaceuticals, Inc. Compositions for treating flushing and lipid-associated disorders comprising niacin receptor partial agonists
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
EP1877402A1 (en) * 2005-04-28 2008-01-16 Merck Sharp & Dohme Limited A process for the preparation of tetrazolyltetrahydrocyclopentapyrazoles
DE602006020447D1 (de) 2005-06-28 2011-04-14 Merck Sharp & Dohme Niacin-rezeptoragonisten, zusammensetzungen mit de
DE102006021733A1 (de) * 2006-05-09 2007-11-22 Bayer Healthcare Ag 3-Tetrazolylindazole und 3-Tetrazolylpyrazolopyridine sowie ihre Verwendung
DE102006043443A1 (de) 2006-09-15 2008-03-27 Bayer Healthcare Ag Neue aza-bicyclische Verbindungen und ihre Verwendung
DE102008063992A1 (de) 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
EP2872127A1 (en) 2012-07-11 2015-05-20 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
JP6386478B2 (ja) 2013-02-21 2018-09-05 アドヴェリオ・ファーマ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング メチル｛４，６−ジアミノ−２−［１−（２−フルオロベンジル）−１ｈ−ピラゾロ［３，４−ｂ］ピリジノ−３−イル］ピリミジノ−５−イル｝メチルカルバメートの形態
US9975910B2 (en) 2013-07-23 2018-05-22 Eisai R&D Management Co., Ltd. Hetero-fused cyclic compound
CN103755637A (zh) * 2013-12-26 2014-04-30 平湖优康药物研发有限公司 一种医药中间体1,4,5,6-四氢-3-环戊并吡唑甲腈的合成工艺
CA3096145A1 (en) * 2019-10-11 2021-04-11 Royal Bank Of Canada System and method of machine learning using embedding networks

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02178263A (ja) * 1988-12-27 1990-07-11 Kaken Pharmaceut Co Ltd アザアズレン誘導体、その製造法およびそれを有効成分とする抗アレルギー剤および抗炎症剤
US5134155A (en) * 1991-08-08 1992-07-28 Ortho Pharmaceutical Corporation Tetrahydroindazole, tetrahydrocyclopentapyrazole, and hexahydrocycloheptapyrazole compounds and their use as HMG-coA reductase inhibitors
US5948786A (en) 1996-04-12 1999-09-07 Sumitomo Pharmaceuticals Company, Limited Piperidinylpyrimidine derivatives
SK86699A3 (en) 1996-12-23 2000-11-07 Du Pont Pharm Co Nitrogen containing heteroaromatics as factor xa inhibitors
ATE451346T1 (de) 1998-03-10 2009-12-15 Ono Pharmaceutical Co Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
JP4292742B2 (ja) 2000-03-09 2009-07-08 小野薬品工業株式会社 インドール誘導体、その製造方法および用途
US20010047027A1 (en) 2000-04-12 2001-11-29 Marc Labelle Prostaglandin D2 receptor antagonists
CN1245974C (zh) 2000-06-28 2006-03-22 特瓦制药工业有限公司 卡维地洛
JP4102185B2 (ja) 2000-06-30 2008-06-18 グラクソ グループ リミテッド キナゾリンジトシル酸塩化合物
US6410583B1 (en) 2000-07-25 2002-06-25 Merck Frosst Canada & Co. Cyclopentanoindoles, compositions containing such compounds and methods of treatment
DE10057751A1 (de) 2000-11-22 2002-05-23 Bayer Ag Neue Carbamat-substituierte Pyrazolopyridinderivate
ES2272712T3 (es) 2001-05-23 2007-05-01 Merck Frosst Canada Ltd. Derivados de dihidropirrolo-1,2-aiindol y tetrahidropirido -1,2-aiindol como antagonistas de receptores de prostaglandina d2.
CN1245391C (zh) 2001-06-01 2006-03-15 弗·哈夫曼-拉罗切有限公司 用作谷氨酸受体的嘧啶、三嗪和吡嗪衍生物
JP4510442B2 (ja) 2001-06-26 2010-07-21 ブリストル−マイヤーズ スクイブ カンパニー ＴＮＦ−α発現のＮ−ヘテロ環インヒビター
DE60200346T2 (de) 2001-06-27 2005-03-24 Rs Tech Corp. Neuer chiraler salen-katalysator und verfahren zur herstellung chiraler verbindungen aus racemischen epoxiden unter verwendung des neuen katalysators
CA2459515A1 (en) 2001-09-07 2003-03-20 Kazuhiko Torisu Indole derivatives
DE10148617A1 (de) 2001-09-25 2003-04-24 Schering Ag Substituierte N-(1,4,5,6-Tetrahydro-cyclopentapyrazol-3-yl)-Derivate, deren Herstellung und Verwendung als Arzneimittel
AR038136A1 (es) 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
RU2329256C2 (ru) 2002-03-19 2008-07-20 Оно Фармасьютикал Ко., Лтд. Производное карбоновой кислоты, фармацевтическая композиция и средство для профилактики и/или лечения заболеваний, вызванных активацией dp-рецептора, применение производного карбоновой кислоты для производства такого средства, способ профилактики и/или лечения заболеваний, вызываемых активацией dp-рецепторов
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
WO2004033431A2 (en) 2002-10-04 2004-04-22 Arena Pharmaceuticals, Inc. Hydroxypyrazoles for use against metabolic-related disorders
US20060167270A1 (en) * 2002-10-10 2006-07-27 Arena Pharmaceuticals Inc. 5-substituted 2h-pyrazone-3-carbixylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia
DE10261131A1 (de) 2002-12-20 2004-07-01 Grünenthal GmbH Substituierte 5-Aminomethyl-1H-pyrrol-2-carbonsäureamide
US7145012B2 (en) 2003-04-23 2006-12-05 Pfizer Inc. Cannabinoid receptor ligands and uses thereof
AR041089A1 (es) 2003-05-15 2005-05-04 Merck & Co Inc Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
US7232823B2 (en) 2003-06-09 2007-06-19 Pfizer, Inc. Cannabinoid receptor ligands and uses thereof
EP1633351A1 (en) 2003-06-13 2006-03-15 Arena Pharmaceuticals, Inc. 5-substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor rup25 for the treatment of dyslipidemia and related diseases
GB0319124D0 (en) 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
GB0319126D0 (en) 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
TWI258478B (en) 2003-10-31 2006-07-21 Arena Pharm Inc Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
WO2005077950A2 (en) 2004-02-14 2005-08-25 Smithkline Beecham Corporation Medicaments with hm74a receptor activity
WO2006026273A2 (en) 2004-08-25 2006-03-09 Merck & Co., Inc. Method of treating atherosclerosis, dyslipidemias and related conditions
AU2005305086A1 (en) 2004-11-05 2006-05-18 Arena Pharmaceuticals, Inc. Compositions for treating flushing and lipid-associated disorders comprising niacin receptor partial agonists
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
EP1877402A1 (en) 2005-04-28 2008-01-16 Merck Sharp & Dohme Limited A process for the preparation of tetrazolyltetrahydrocyclopentapyrazoles

Also Published As

Publication number Publication date
DE602004001134D1 (de) 2006-07-20
CA2539985C (en) 2010-02-16
PT1599469E (pt) 2006-10-31
TW200530221A (en) 2005-09-16
CO5690551A2 (es) 2006-10-31
JP4533898B2 (ja) 2010-09-01
CY1105479T1 (el) 2010-07-28
MY140410A (en) 2009-12-31
CA2539985A1 (en) 2005-05-19
CR8270A (es) 2006-10-06
MXPA06004556A (es) 2006-07-06
MA28171A1 (fr) 2006-09-01
EA200600879A1 (ru) 2006-10-27
DK1599469T3 (da) 2006-10-09
NZ546285A (en) 2010-04-30
HRP20060286T3 (en) 2007-03-31
US20060217562A1 (en) 2006-09-28
IL174042A0 (en) 2006-08-01
EP1683794A1 (en) 2006-07-26
TNSN06150A1 (en) 2007-11-15
ZA200606203B (en) 2007-04-25
SI1599469T1 (sl) 2006-10-31
JP2010163448A (ja) 2010-07-29
CN1867562A (zh) 2006-11-22
IS8481A (is) 2006-05-24
EA011484B1 (ru) 2009-04-28
PE20050483A1 (es) 2005-08-25
EP1599469A1 (en) 2005-11-30
ATE328880T1 (de) 2006-06-15
RS20060290A (en) 2008-11-28
AU2004287861B2 (en) 2008-08-14
US20070072924A1 (en) 2007-03-29
WO2005044816A1 (en) 2005-05-19
CN1867562B (zh) 2011-07-13
ES2267077T3 (es) 2007-03-01
ZA200603419B (en) 2006-10-25
KR100850591B1 (ko) 2008-08-05
JP2007509181A (ja) 2007-04-12
AR046611A1 (es) 2005-12-14
ECSP066529A (es) 2006-10-10
GEP20094801B (en) 2009-10-26
IS2372B (is) 2008-06-15
DE602004001134T2 (de) 2007-04-19
BRPI0415631A (pt) 2006-12-12
US8637555B2 (en) 2014-01-28
HK1076468A1 (en) 2006-01-20
UA86783C2 (ru) 2009-05-25
PL1599469T3 (pl) 2006-10-31
KR20060073974A (ko) 2006-06-29
AU2004287861A1 (en) 2005-05-19
EP1599469B1 (en) 2006-06-07
TWI258478B (en) 2006-07-21

Similar Documents

Publication Publication Date Title
NO20062509L (no) Tetrazolderivater og fremgangsmater for behandling av stoffskifterelaterte forstyrrelser derav
NO20073766L (no) Smeltede pyrazolderivater og fremgangsmater for behandling av metabolsk-relaterte lidelser derav
WO2004033431A3 (en) Hydroxypyrazoles for use against metabolic-related disorders
EP3129023B1 (en) Potent soluble epoxide hydrolase inhibitors
US9447134B2 (en) Compounds and methods for treating mammalian gastrointestinal microbial infections
PH12014500937A1 (en) 5-ht 1a receptor substype agonist
MX2007010532A (es) Derivados de amida de acido 1-sulfonil-piperidina-3-carboxilico como inhibidores de 11-beta-hidroxiesteroide deshidrogenasa para el tratamiento de diabetes mellitus tipo ii.
NZ587547A (en) Modulators of ATP-Binding Cassette Transporters
CA2537127A1 (en) Benzimidazolone compounds having 5-ht4 receptor agonistic activity
MX2009006474A (es) Derivados de benzamida como agonistas del receptor ep4.
MX2011012627A (es) Derivados aminobutiricos sustituidos como inhibidores de nepralisina.
CA2554550A1 (en) Hydroisoindoline tachykinin receptor antagonists
CA2615611A1 (en) Indazole derivatives
CA2545092A1 (en) Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity
NO20084674L (no) 1- [ (4-(benzoyl (metyl) amino] -3- (fenyl) butyl] azetidinderivater for behandling av gastrointestinale lidelser
JP5765738B2 (ja) ロスバスタチンおよびアトルバスタチン誘導体
DE60327446D1 (de) 5-substituierte 2h-pyrazon-3-carbonsäure-derivate als antilipolytische mittel zur behandlung von stoffwechselstörungen, wie z.b. dyslipidemie
WO2003018010A1 (fr) Agent prophylactique et/ou curatif pour les maladies induites par l'activite de l'arteriosclerose
WO2005051937A3 (en) 4-oxo-4,5-dihydro-furan-2-carboxylic and acid derivatives and methods of treatment of metabolic-related disorders thereof
Kato et al. Discovery of 2, 8-diazaspiro [4.5] decane-based trisubstituted urea derivatives as highly potent soluble epoxide hydrolase inhibitors and orally active drug candidates for treating hypertension
UA90878C2 (ru) Конденсированные производные пиразола и способы лечения с их помощью заболеваний, вызванных нарушением обмена веществ
WO2008146917A1 (ja) リンコマイシン誘導体及びこれを有効成分とする抗菌剤
TNSN08287A1 (en) 3,5-substituted piperidine compounds as renin inhibitors
WO2003018564A1 (fr) Inhibiteur d'acat selectif de la paroi vasculaire
FR2926817A1 (fr) Derives d'uree de tetrahydroquinoxaline, leur preparation et leur application en therapeutique

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application